Characteristics of patients from population-based evaluation (n = 54) and patients treated with IVE/MTX (n = 26)
| . | Population-based evaluation, n/N (%) . | IVE/MTX, n/N (%) . |
|---|---|---|
| Median age, y (range) | 57 (28-82) | 56 (36-69) |
| Female sex | 21/54 (39) | 9/26 (35) |
| Lugano stage | ||
| I | 8/53 (15) | 4/26 (15) |
| II 1 | 8/53 (15) | 5/26 (19) |
| II 2 | 6/53 (11) | 2/26 (8) |
| II E | 0/53 (0) | 3/26 (12) |
| II 1E | 0/53 (0) | 6/26 (23) |
| II 2E | 21/53 (40) | 1/26 (4) |
| IV | 10/53 (19) | 5/26 (19) |
| Manchester stage | ||
| Ia | 5/53 (9) | 1/26 (4) |
| Ib | 3/53 (6) | 3/26 (12) |
| IIa | 8/53 (15) | 5/26 (19) |
| IIb | 4/53 (8) | 5/26 (19) |
| IIc | 17/53 (32) | 4/26 (15) |
| III | 6/53 (11) | 3/26 (12) |
| IV | 10/53 (19) | 5/26 (19) |
| Site of disease in GT | ||
| Jejunum/ileum | 52/54 (96) | 22/26 (84) |
| Stomach/duodenum | 0/54 (0) | 2/26 (8) |
| Duodenojejunal flexure | 1/54 (2) | 2/26 (8) |
| Ileocecal | 1/54 (2) | 0/26 (0) |
| Bone marrow involvement | 2/33 (6) | 1/22 (5) |
| ECOG greater than 1 | 46/52 (88) | 20/26 (77) |
| Presenting features | ||
| Pain | 43/53 (81) | 25/26 (96) |
| Lump | 3/53 (6) | 1/26 (4) |
| Nausea/vomiting | 2/53 (38) | 18/26 (69) |
| Weight loss | 30/53 (57) | 19/26 (73) |
| Bowel upset | 17/53 (32) | 15/26 (58) |
| Perforation | 21/53 (40) | 8/26 (31) |
| Subacute obstruction | 16/53 (30) | 10/26 (39) |
| Duration of symptoms before diagnosis | ||
| 0-1 mo | 17/51 (33) | 6/25 (24) |
| 1-3 mo | 13/51 (26) | 7/25 (28) |
| 3-6 mo | 15/51 (29) | 5/25 (20) |
| Longer than 6 mo | 6/51 (12) | 7/25 (28) |
| Presence of celiac disease | 48/52 (92) | 19/26 (73) |
| Before diagnosis | 18/52 (34) | 11/26 (42) |
| At diagnosis | 30/52 (58) | 8/26 (31) |
| Diagnosis at | ||
| Surgery | 49/54 (91) | 23/26 (89) |
| Endoscopy | 4/54 (7) | 3/26 (11) |
| Postmortem | 1/54 (2) | 0/26 (0) |
| Abnormal hemoglobin | 27/50 (54) | 11/26 (42) |
| Abnormal WBC count | 18/50 (36) | 9/26 (35) |
| Abnormal kidney function | 16/50 (32) | 11/25 (44) |
| Abnormal liver function | 39/51 (76) | 16/25 (64) |
| Abnormal LDH | 11/26 (42) | 9/19 (47) |
| . | Population-based evaluation, n/N (%) . | IVE/MTX, n/N (%) . |
|---|---|---|
| Median age, y (range) | 57 (28-82) | 56 (36-69) |
| Female sex | 21/54 (39) | 9/26 (35) |
| Lugano stage | ||
| I | 8/53 (15) | 4/26 (15) |
| II 1 | 8/53 (15) | 5/26 (19) |
| II 2 | 6/53 (11) | 2/26 (8) |
| II E | 0/53 (0) | 3/26 (12) |
| II 1E | 0/53 (0) | 6/26 (23) |
| II 2E | 21/53 (40) | 1/26 (4) |
| IV | 10/53 (19) | 5/26 (19) |
| Manchester stage | ||
| Ia | 5/53 (9) | 1/26 (4) |
| Ib | 3/53 (6) | 3/26 (12) |
| IIa | 8/53 (15) | 5/26 (19) |
| IIb | 4/53 (8) | 5/26 (19) |
| IIc | 17/53 (32) | 4/26 (15) |
| III | 6/53 (11) | 3/26 (12) |
| IV | 10/53 (19) | 5/26 (19) |
| Site of disease in GT | ||
| Jejunum/ileum | 52/54 (96) | 22/26 (84) |
| Stomach/duodenum | 0/54 (0) | 2/26 (8) |
| Duodenojejunal flexure | 1/54 (2) | 2/26 (8) |
| Ileocecal | 1/54 (2) | 0/26 (0) |
| Bone marrow involvement | 2/33 (6) | 1/22 (5) |
| ECOG greater than 1 | 46/52 (88) | 20/26 (77) |
| Presenting features | ||
| Pain | 43/53 (81) | 25/26 (96) |
| Lump | 3/53 (6) | 1/26 (4) |
| Nausea/vomiting | 2/53 (38) | 18/26 (69) |
| Weight loss | 30/53 (57) | 19/26 (73) |
| Bowel upset | 17/53 (32) | 15/26 (58) |
| Perforation | 21/53 (40) | 8/26 (31) |
| Subacute obstruction | 16/53 (30) | 10/26 (39) |
| Duration of symptoms before diagnosis | ||
| 0-1 mo | 17/51 (33) | 6/25 (24) |
| 1-3 mo | 13/51 (26) | 7/25 (28) |
| 3-6 mo | 15/51 (29) | 5/25 (20) |
| Longer than 6 mo | 6/51 (12) | 7/25 (28) |
| Presence of celiac disease | 48/52 (92) | 19/26 (73) |
| Before diagnosis | 18/52 (34) | 11/26 (42) |
| At diagnosis | 30/52 (58) | 8/26 (31) |
| Diagnosis at | ||
| Surgery | 49/54 (91) | 23/26 (89) |
| Endoscopy | 4/54 (7) | 3/26 (11) |
| Postmortem | 1/54 (2) | 0/26 (0) |
| Abnormal hemoglobin | 27/50 (54) | 11/26 (42) |
| Abnormal WBC count | 18/50 (36) | 9/26 (35) |
| Abnormal kidney function | 16/50 (32) | 11/25 (44) |
| Abnormal liver function | 39/51 (76) | 16/25 (64) |
| Abnormal LDH | 11/26 (42) | 9/19 (47) |
IVE/MTX indicates ifosfamide, vincristine, and etoposide/methotrexate; GT, gastrointestinal tract; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell; and LDH, lactate dehydrogenase.